Broadwood Partners Issues Letter to STAAR Surgical's Board Questioning Its Judgment in Proposed Sale to Alcon
Contends There Is No Business Justification for the Board's Decision to Sell the Company for $28 Per Share Now After Rejecting $58 Per Share from Alcon Last Year Encourages Shareholders to Vote "AGAINST" the Proposed Acquisition NEW YORK — Broadwood Partners,
(Financial Post, 2025-10-06T12:35:36Z)